Endocrine treatment and follow-up in thyroid carcinoma;Endokrine therapie und nachsorge beim schilddrüsenkarzinom

Praxis

Volumn 87, Issue 11, 1998, Pages 389-393

  Feldkamp, J ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Follow up; Radioiodine treatment; THS suppressive therapy; Thyroglobulin; Thyroid carcinoma

Indexed keywords

THYROTROPIN; THYROXINE;

AFTERCARE; BLOOD; CANCER STAGING; CARCINOMA; HUMAN; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REVIEW; THYROID TUMOR;

AFTERCARE; CARCINOMA; COMBINED MODALITY THERAPY; HUMANS; NEOPLASM STAGING; THYROID NEOPLASMS; THYROTROPIN; THYROXINE;

EID: 0032507194     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Biondi B., Fazio S., Carella C., Amato G., Cittadini A., Lupoli G., Sacca L., Bellastetla A., Lombardi G., Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J. Clin. Endocrinol. Metab. 77, 334-338, 1993.
2. De Groot L. J., Kaplan E. L., McCormick M., Straus F. H.: Natural history, treatment, and course of papillary thyroid carcinoma. Clin. Endocrinol. Metab. 71, 414-24, 1990.
3. De Groot L.J., Kaplan E. L., Straus F. H., Shukla M. S.: Does the method of management of papillary thyroid carcinoma make a difference in outcome? World J. Surg. 18, 123-130, 1994.
4. Dralle H., Schwarzrock R., Lang W., Böcker W., Ziegler H., Schröder S., Geerlings H.: Comparison of histology and immuno-histochemistry with thyroglobulin serum levels and radioiodine uptake in recurrences and metastases of differentiated thyroid carcinomas. Acta endocrinol. 108, 504-510, 1985.
5. Eising E. G., Farahati J., Bier D., Knust E. J., Reiners C.: Somatostatinrezeptorszintigraphie bei medullären Schilddrüsenkarzinomen, GEP-Tumoren und Karzinoiden. Nucl. Med. 34, 1-7, 1995.
6. Girelli M. E., Busnardo B., Amerio R., Scottoni G., Casara D., Betterle C., Picolo M., Pelizzo M. R.: Serum thyroglobulin levels in patients with well-differentiated thyroid cancer during suppression therapy. Study on 429 patients. Europ J. Nucl. Med. 10, 252-254, 1985.
7. Goretzki P. E., Frilling A., Ohmann C. Wins L., Grussendorf M., Röher H. D.: Unterschiedliche Strategien in Diagnostik und Therapie des Schilddrüsenkarzinoms. Chirurg 60, 398-402, 1989.
8. Hay I. D., Bergstralh E. J., Goellner J. R., Ebersold J. R., Grant C. S.: Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989, Surgery 114, 1050-1058, 1993.
9. Hedinger C., Williams E. D., Sobin L. H.: Histologic typing of thyroid tumours. In: International hislological classification of tumors. WHO. Springer Verlag, New York, 1988.
10. Lips C. J. M., Landsvater R. M., Höppener W. M., Geerding R. A., Blijham G., van Veen J. M., van Gils A. P., de Wit M. J., Zewald R. A., Berends M. J. et al.: Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia Type 2a. N. Engl. J. Med. 331, 828-835, 1994.
11. Kerr D. J., Burt A. D., Boyle P.: Prognostic factors in thyroid tumors. Br. J. Cancer 54, 475-482, 1986.
12. Mazzaferri E. L., Sissy M., Jhiang S. M.: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 97, 418-429, 1994.
13. Mueller-Gaertner H. W., Brzac H. T., Rehpenning W.: Prognostic indices for tumor relapse and tumor mortality in follicular thyroid carcinoma. Cancer 67, 1903-22, 1991.
14. Mulligan L. M., Kwok J. B. J., Healey C. S., Elsdon M. J., Eng C., Gardner E., Love D. R., Mole S. E., Moore J. K., Papi L., Ponder M. A., Telenius H., Tunnacliffe A., Ponder B. A. J.: Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2a (MEN ). Nature 363, 458-469, 1993.
15. Raue F., Frank-Raue K., Grauer A.: Multiple endocrine neoplasia type 2, clinical features, and screening. Endocrin. Metab. Clin. North Am. 23, 137-156, 1994.
16. Panza N., de Rosa M., Lombardi G., Salvatore M.: Usefulness of serum thyroglobulin at replacement withdrawal after thyroidectomy for differentiated thyroid cancer. J. Nucl. Med. 26, 316-317, 1985.
17. Röher H. D., Simon D., Witte J., Goretzki P. E.: Principals of limited or radical surgery for differentiated thyroid cancer. Thyroidology 5, 93-96, 1994.
18. Samaan N. A., Schultz P. N., Hickey R. C., Goepfert H., Haynie T. P., Johnston D. A., Ordonez N. G.: The results of various modalities of treatment of well differentiated thyroid carcinoma: a retrospective review of 1599 patients. J. Clin. Endocrinol. Metab. 75, 714-720, 1992.
19. Sawin C. T., Geller A., Wolf P. A., Belanger A. J., Baker E., Bacharach P., Wilson P. W., Benjamin E. J., D'Agostino R. B.: Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N. Engl. J. Med. 331, 1249-1252, 1994.
20. Schelfhout L. J., Creutzberg C. L., Hamming J. F., Fleuren G. J., Smeenk D., Hermans J., van de Velde C. J., Goslings B. M.: Multivariate analysis of survival in differentiated thyroid cancer: the prognostic significance of the age factor. Eur. J. Cancer Clin. Oncol. 24, 331-337, 1988.
21. Schlumberger M., Tubiana M., de Vathaire F., Hill C., Gardet P., Travagli J. P., Fragu P., Lumbroso J., Caillou B., Parmentier C.: Long-term results of treatment of 283 patients with lung and hone metastases from differentiated thyroid carcinoma J. Clin. Endocrinol. Metab. 63, 960-966, 1986.
22. Sherman S. T., Tielens E. T., Sostre S., Wharam Jr M. D., Ladenson P. W.: Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J. Clin. Endocrinol. Metab. 78, 629-634, 1994.
23. Solbiati L., Volterrani L., Rizzatto G., Bazzocchi M., Busilacci P., Candiani F., Ferrari F., Giuseppetti G., Maresca C., Mirk P. et al: The thyroid gland with low uptake lesions: evaluation by ultrasound. Radiology 155, 187-191, 1985.
24. Solomon B. L., Wartowsky L., Burman D.: Current trends in the management of well differentiated papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 81, 333-339, 1996.
25. Uzzan B., Campos J., Cucherat M., Nony P., Boissel J. P., Perret G. Y.: Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J. Clin. Endocrinol. Metab. 81, 4278-4289, 1996.
26. Van de Velde C. J. H., Hamming J. F., Goslings B. M. et al.: Report on the consensus development conference on the management of differentiated thyroid cancer in the Netherlands. Eur J. Cancer Clin. Oncol. 24, 287-292, 1988.
27. Wahl R. A., Röher H. D.: Surgery for C-cell-carcinoma of the thyroid. Progr. Surg. 19, 100-112, 1988.
28. Wartofsky L.: Does replacement thyroxine therapy cause osteoporosis? Adv. Endocrinol. Metab. 4, 157-175, 1993.